BGI-North has established a series of technology platforms including Sanger Sequencing Platform, High-throughput Sequencing Platform, Synthesis Platform, Clinical Diagnostics Platform, Proteomics Platform.
The Sanger Sequencing Platform
In BGI North Region, “Promotion comes from tasks” is the guide line of the Sanger sequencing platforms. Since BGI’s foundation, this platform has undertook and completed many top-level sequencing projects, including 1% of the Human Genome Project, the International HapMap Project, the draft sequence of the rice genome and the First Asian Genome Map. BGI-North gathered wider experience on sequencing and bioinformatics analysiss.
The current platform has more than 10 Sanger sequencers, most of which are AB 3730xl. For making better use of the laboratory, the platform explores its own management system and obtains the international certification of ISO9001:2008. Its advanced laboratory management and high quality service provide forceful guarantee for the Sanger sequencing platform in maintaining its competitiveness.
High-throughput Sequencing Platform
The high-throughput sequencing platform has already established the standardized high-throughput laboratory with many high-throughput sequencers like Illumina Hiseq 2000. Now, the platform can carry out a variety of sequencing services, including DNA sequencing, RNA sequencing, small-RNA sequencing, transcriptase sequencing, digital gene expression tag profiling (DGE), ChIP-Seq, DNA methylation checking, target region capture sequencing and metagenomic sequencing.
Taking full advantages BGI's talents and technology, the platform will optimize and improve the existing high-throughput sequencing platform to meet the growing market demands. At the same time, the platform will keep up with the latest international progress to expand the application of sequencing technology in scientific research and practice.
Synthesis Technology Platform
The synthesis technology platformis equipped with 192-synthesizers, which could synthesize hundreds of thousands of bases per day and provide various sequencing and synthesis services. The platform has already established a strict quality control system and efficient deliver channel, which would make synthesized service more timely provided in high quality.
Clinical Diagnostics Platform
In March 2011, BGI Unicare Technology Co, ltd was built in Beijing, which was the first to explore non-invasive prenatal screening service for detecting fetal aneuploidy diseases. Currently, BGI Unicare has established stable corporations with many famous medical institutions in China, and it also succeed in taking the non-invasive prenatal screening technology into application with the advantages of non-invasive, safe, and accurate.
|Go to the Clinic -- BGI-Healthcare is taking the action|
With the development of Med Lab of BGI-Tianjin, BGI-Beijing and BGI-Benxi, BGI North Region started to build an overall new platform for clinical testing and medical diagnostic center. Now, the platform can provide many health-associated service and screening and diagnosis of some genetic diseases, including HLA high resolution typing, HPV Genotyping, drug-resistant genes' screening of HBV, drug-targets instruction in cancer individual cure, analysis of thalassemia's genotype, non-invasive prenatal genetic testing of fetal chromosomal aneuploidy (especially for Down syndrome), screening of the deafness gene in new-born, testing of the genetic metabolize disease in new-born and the test of genetic breast cancer.
Protein Technology Platform
Based on dimensional electrophoresis and mass spectrum identification, BGI Protein Technology Platform developed multiple tag McAb and clinical IHC diagnosis McAb and molecular biology tool enzymes like reverse transcriptase. At the same time, the world's largest rice antibody database and the preparation for thousands of antibody have been completed.
In the process of development, BGI protein R&D center has gradually improved the SOP, as well as developed and expanded the new database system. In 2010, BGI protein has successfully passed annual review of the ISO quality management system and approved in the certification of high technology enterprise.
The Proteomics Platform
Based on the experience of dimensional electrophoresis and mass spectrum identification, the proteomics platform provides Itraq quantified service. Since it was built, various types of research has been accomplished with its help, such as the research on monoclonal antibody of tag or clinical IHC diagnostics, tool-enzyme in molecular biology, like reverse transcriptase. Additionally, the platform has built the global largest antibody database of rice which has produced more than 1000 antibodies. Their work on technology transform and patent application has also got breakout recently.
The protein research center of BGI-Beijing Co. Ltd developed and optimized SOP to achieve the company's goals. They also built and complemented new database system independently, which could fulfill the data communication and storage requirements inside of the company. In 2010, they passed the annual verification of ISO quality management system was passed and the national high-tech enterprise certification was obtained.
Diagnostic kit Research and Industrialization
BGI-GBI has built five core technology platforms, which has more than forty mature products approved by SFDA. In 2001, 2005, 2010, GBI completed the national GMP certification, and got the national IVD certification and ISO9001 certification
BGI-GBI’s diagnostic products include ELISA, nucleic acid diagnostics, Array-ELISA, chemiluminescence and colloidal gold, etc. Blood screening is the main enzyme products. TP has proprietary intellectual property rights. HBV and HCV have been widely used in blood screening and clinical. AE mainly contains six tumor marker assay kits and autoimmune disease ENA antibody repertoire diagnostic kits.
Judicial material evidence
Center of Forensic Sciences is the first organization recognized as independent third-party judicial expertise. Now its services involved include: medico legal expertise (Parentage testing using DNA, other paternity testing, DNA establishing identity and DNA database), animal and plant life gene identification.
- [news]CFDA Approved Next Generation Sequencing Diagnostic Products
- [news]BGI announces world-leading research centre with the University of Birmingham
- [news]Four BGI Researchers Listed as Thomson Reuters’ Highly Cited
- [news]BGI Ranked 5th of NPI 2013 Top 10 Chinese Institutions
- [news] BGI Listed as Fast Company’s 2014 World’s 50 Most Innovative Companies
- [news]BGI Ranked 119 of Global Top 200 Scientific Institutions in 2012
BGI North China
Address: Building C2-2/3, R& Dcenter, Shiqiaozi Mulan Road, High-tech Zone, Benxi, Liaoning Province, 117004, China
BGI East China
BGI Central China
Address: No. 389 Haiyuan Road, High-tech Development Zone, Kunming, Yunnan, 650106, China
BGI Northwest China
Address(Prepared): Administration Building, No. 6 Xinqiao Road, Yangling District, Xi’an, Shanxi, 712100, China
BGI South China
BGI TibetAddress: No. 189, Jinzhu West Road, Lhasa, 850000, China